Pages that link to "Q46235664"

The following pages link to A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer (Q46235664):

Displaying 31 items.

• Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer (Q24186509) (← links)
• Optimal primary surgical treatment for advanced epithelial ovarian cancer (Q24234923) (← links)
• Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer (Q24235235) (← links)
• Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer (Q24244876) (← links)
• Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses (Q33269777) (← links)
• Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care (Q33279245) (← links)
• PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice (Q33896659) (← links)
• Pursuit of optimum outcomes in ovarian cancer: methodological approaches to therapy (Q34315086) (← links)
• Phase ii/iii study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: ncic ctg ov.21. (Q34628651) (← links)
• Intraperitoneal chemotherapy for ovarian cancer: a question of feasibility? (Q35214612) (← links)
• Historical progress in the initial management of ovarian cancer: intraperitoneal chemotherapy (Q36623377) (← links)
• Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer? (Q37202777) (← links)
• Intraperitoneal chemotherapy of ovarian cancer (Q37608431) (← links)
• Achievements and unmet needs in the management of advanced ovarian cancer (Q37670385) (← links)
• Intraperitoneal Chemotherapy: Why the Fuzz? (Q37807369) (← links)
• Current and future directions of clinical trials for ovarian cancer (Q37832932) (← links)
• Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics (Q37993908) (← links)
• Ovarian cancer: advances in first-line treatment strategies with a particular focus on anti-angiogenic agents. (Q38040628) (← links)
• Intraperitoneal chemotherapy in advanced epithelial ovarian cancer: a survey (Q38213258) (← links)
• Cytoreductive surgery and intraoperative administration of paclitaxel-loaded expansile nanoparticles delay tumor recurrence in ovarian carcinoma (Q39249056) (← links)
• Effects of granulocyte-colony stimulating factor on peritoneal defense mechanisms and bacterial translocation after administration of systemic chemotherapy in rats (Q42210083) (← links)
• CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study (Q44099206) (← links)
• Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: a single institution's experience (Q45209332) (← links)
• Clinical studies in CRS and HIPEC: Trials, tribulations, and future directions-A systematic review. (Q47849422) (← links)
• Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer (Q47950482) (← links)
• Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease (Q50506495) (← links)
• Intraperitoneal access via direct puncture is an alternative way to deliver intraperitoneal chemotherapy in ovarian, fallopian tube and primary peritoneal cancer (Q51833127) (← links)
• Inverse targeting of peritoneal tumors: selective alteration of the disposition of methotrexate through the use of anti-methotrexate antibodies and antibody fragments (Q71736880) (← links)
• Intraperitoneal chemotherapy for ovarian cancer (Q79105780) (← links)
• Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma (Q83170387) (← links)
• Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial (Q89094825) (← links)